1. McCluskey L, Vandriel S, Elman L, et al. ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. J Neurol Sci. 2014;345(1-2):118-124.
2. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918-1929.
3. Brigo F, Bovi T, Ferigo L, et al. Head drop in progressive supranuclear palsy: an unusual association with amyotrophic lateral sclerosis. Parkinsonism Relat Disord. 2013;19(4):467-468.
4. Van Mossevelde S, Van der Zee J, Gijselinck I, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain. 2016;139(Pt 2):452-467.
5. Liu FT, Wang J, Chen Y. Lost Dopaminergic Bindings in the Caudate of a Patient With Frontotemporal Lobar Degeneration-Motor Neuron Disease. JAMA Neurol. 2020;77(11):1448-1449.
6. Wilke C, Baets J, De Bleecker JL, et al. Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiol Aging. 2018;62:244 e249-244 e213.
7. Van Langenhove T, van der Zee J, Van Broeckhoven C. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med. 2012;44(8):817-828.
8. Strong MJ, Donison NS, Volkening K. Alterations in Tau Metabolism in ALS and ALS-FTSD. Front Neurol. 2020;11:598907.
9. Tagai K, Ono M, Kubota M, et al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. Neuron. 2021;109(1):42-58 e48.
10. Li L, Liu F-T, Li M, et al. Clinical Utility of 18F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. [In Press] Mov Disord. 2021.
11. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497-503.
12. Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32(6):853-864.
13. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477.
14. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1-2):13-21.
15. Zhou XY, Wu JJ, Sun YM. An atypical case of early-onset dystonia with a novel missense variant in KMT2B. Parkinsonism Relat Disord. 2019;63:224-226.
16. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
17. Cleary EM, Pal S, Azam T, et al. Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. Mol Cell Probes. 2016;30(4):218-224.
18. Liu FT, Ge JJ, Wu JJ, et al. Clinical, Dopaminergic, and Metabolic Correlations in Parkinson Disease: A Dual-Tracer PET Study. Clin Nucl Med. 2018;43(8):562-571.
19. Brendel M, Barthel H, van Eimeren T, et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020;77(11):1408-1419.
20. Gijselinck I, Van Mossevelde S, van der Zee J, et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015;85(24):2116-2125.
21. Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C. Genotype-phenotype links in frontotemporal lobar degeneration. Nat Rev Neurol. 2018;14(6):363-378.
22. Sobue G, Ishigaki S, Watanabe H. Pathogenesis of Frontotemporal Lobar Degeneration: Insights From Loss of Function Theory and Early Involvement of the Caudate Nucleus. Front Neurosci. 2018;12:473.
23. Xu D, Jin T, Zhu H, et al. TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. Cell. 2018;174(6):1477-1491 e1419.
24. Tsai RM, Bejanin A, Lesman-Segev O, et al. (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;11(1):13.
25. Bevan-Jones WR, Cope TE, Jones PS, et al. [(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89(10):1032-1037.
26. Bevan-Jones RW, Cope TE, Jones SP, et al. [(18)F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. Ann Clin Transl Neurol.. 2018;5(10):1292-1296.
27. Fujita K, Matsubara T, Miyamoto R, et al. Co-morbidity of progressive supranuclear palsy and amyotrophic lateral sclerosis: a clinical-pathological case report. BMC Neurol. 2019;19(1):168.
28. Takeuchi R, Toyoshima Y, Tada M, et al. Globular Glial Mixed Four Repeat Tau and TDP-43 Proteinopathy with Motor Neuron Disease and Frontotemporal Dementia. Brain Pathol. 2016;26(1):82-94.
29. Abreha MH, Ojelade S, Dammer EB, et al. TBK1 interacts with tau and enhances neurodegeneration in tauopathy. J Biol Chem. 2021:100760.